Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Mee Joo Kang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9289-3808; OpenAlex author ID A5008731225. Sources: OpenAlex.

Their work

Papers
15 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 15

  1. Increased diagnosis of hepato-biliary-pancreatic cancer after cholecystectomy: a population-based study. Co-author DOI 10.1038/s41598-024-84781-7↗
  2. Epidemiology and survival analysis according to the histologic subtype of pancreatic cancer: a population-based cohort study. First author DOI 10.4174/astr.2025.108.1.20↗
  3. Conditional Relative Survival of Exocrine Pancreatic Cancer: A Population-Based Study. Co-author DOI 10.1245/s10434-023-14594-x↗
  4. Exocrine pancreatic cancer as a second primary malignancy: A population-based study. Co-author DOI 10.14701/ahbps.23-053↗
  5. Incidence, mortality and survival of gallbladder, extrahepatic bile duct, and pancreatic cancer using Korea central cancer registry database: 1999-2019. Co-author DOI 10.14701/ahbps.22-041↗
  6. Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea. Co-author DOI 10.3346/jkms.2022.37.e216↗
  7. First Course of treatment and Prognosis of Exocrine Pancreatic Cancer in Korea from 2006 to 2017. Co-author DOI 10.4143/crt.2021.421↗
  8. Paradigm shift for defining the resectability of pancreatic cancer. Co-author DOI 10.14701/ahbps.2021.25.4.451↗
  9. Clinical significance of defining borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2017.12.003↗
  10. The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic canc… Co-author DOI 10.1016/j.hpb.2015.06.001↗
  11. Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value. Co-author DOI 10.1111/jgh.13253↗
  12. Integrative analysis of multi-omics data for identifying multi-markers for diagnosing pancreatic cancer. Co-author DOI 10.1186/1471-2164-16-s9-s4↗
  13. Identifying molecular subtypes related to clinicopathologic factors in pancreatic cancer. First author DOI 10.1186/1475-925x-13-s2-s5↗
  14. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associa… Co-author DOI 10.1097/mpa.0b013e3182954137↗
  15. Cancer cells with p53 deletion detected by fluorescent in situ hybridization in peritoneal drainage fluid is correlated with early peritoneal seeding in resect… Co-author DOI 10.4174/jkss.2013.84.4.209↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sang‐Jae Park · 7 shared papers, 2022–2025 · strength 1.66
  2. Sung‐Sik Han · 7 shared papers, 2013–2025 · strength 1.47
  3. Hyeong Min Park · 6 shared papers, 2022–2025 · strength 1.43
  4. Sun‐Whe Kim · 10 shared papers, 2013–2023 · strength 1.19
  5. Kyu‐Won Jung · 4 shared papers, 2022–2025 · strength 0.98
  6. Young‐Joo Won · 3 shared papers, 2022–2023 · strength 0.54
  7. Jin‐Young Jang · 6 shared papers, 2013–2018 · strength 0.36
  8. Young Ae Kim · 1 shared paper, 2025 · strength 0.30
  9. Wooil Kwon · 4 shared papers, 2013–2018 · strength 0.26
  10. Taesung Park · 3 shared papers, 2014–2016 · strength 0.15
  11. Junghyun Namkung · 2 shared papers, 2015–2016 · strength 0.11
  12. Seungyeoun Lee · 2 shared papers, 2014–2015 · strength 0.09
  13. Woohyun Jung · 1 shared paper, 2016 · strength 0.07
  14. Jin‐Young Jang · 1 shared paper, 2016 · strength 0.06
  15. Shinuk Kim · 1 shared paper, 2014 · strength 0.05
  16. Min‐Seok Kwon · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.